INTERNATIONAL JOURNAL OF PHARMA PROFESSIONAL'S RESEARCH



Pharmacotherapy Strategies for Metabolic and Endocrine Disorder

Shailender Mishra[1]*, Roopam Tomar[1], Sushmita Mishra[1], Sakshi Sharma[2]
[1]Sunder Deep Pharmacy College, Dasna, Ghaziabad
[2]Accurate College of Pharmacy, Knowledge Park 3rd, Greater Noida

Keywords:
Pharmacotherapy, Metabolic disorders, Endocrine disorders, Diabetes mellitus, Obesity, Adherence, Individualized treatment

Corresponding Author-
Shailender Mishra
Email: shailendramishra847@gmail.com
Sunder Deep Pharmacy College, Dasna, Ghaziabad

Volume 15, Issue 2, 2024
Received: 12 April 2024
Accepted: 15 April 2024
Published: 30 April 2024
DOI: 10.69580/IJPPR.15.2.2024.74-81

ABSTRACT: Metabolic and endocrine disorders encompass a broad spectrum of conditions with significant health implications. Effective pharmacotherapy plays a pivotal role in the management of these disorders, aiming to alleviate symptoms, improve quality of life, and mitigate long-term complications. This review provides a comprehensive overview of current pharmacotherapy strategies for various metabolic and endocrine disorders, including diabetes mellitus, obesity, dyslipidemia, thyroid disorders, adrenal disorders, pituitary disorders, and gonadal disorders. Key oral and injectable medications, their mechanisms of action, and clinical efficacy are discussed. Additionally, challenges such as medication adherence, side effects, individualized treatment approaches, and emerging therapies are addressed. Through this review, we aim to provide clinicians with valuable insights into evidence-based pharmacotherapy strategies to optimize patient outcomes in the management of metabolic and endocrine disorders.

1. Introduction

Metabolic disorders are inborn errors of metabolism that occur when the metabolism process or certain organs fail to function properly. These disorders may be a result of genetic defects, hormone or enzyme deficiency, or abnormal chemical reactions that hinder metabolism. Examples of metabolic disorders include hyperlipidemia, osteoporosis, cystic fibrosis, phenylketonuria (PKU), and diabetes mellitus.[1,2] Endocrine disorders, on the other hand, involve an abnormality of the body's endocrine glands, which can lead to overproduction or underproduction of certain hormones. Endocrine glands are responsible for releasing specific hormones into the circulatory system, affecting the functions of many organs. Examples of endocrine disorders include

hyperthyroidism, hypothyroidism, adrenal hyperplasia, diabetes mellitus, Cushing's syndrome, and insulin resistance. Both metabolic and endocrine disorders can affect various significant functions of the body, such as metabolism, growth and development, sexual function, and reproduction. These disorders can lead to a wide range of effects on the body due to the delicate balance of hormones being thrown off. Treatments for these diseases depend on the specific disorder and have improved for many of these diseases. The complex genetic and environmental factors that underlie their progression may provide avenues to prevention and new therapies.[3–5]

Pharmacotherapy plays a crucial role in healthcare by providing effective treatment for a wide range of illnesses and conditions. It has evolved to become a cornerstone in managing various health issues, offering solutions that can significantly impact patients' well-being and quality of life. Pharmacotherapy is essential in addressing diseases, managing symptoms, and improving overall health outcomes, especially in older patients undergoing rehabilitation or individuals with chronic conditions. The importance of pharmacotherapy lies in its ability to complement other forms of treatment, such as rehabilitation, by focusing on disease management and ensuring that medications are appropriately prescribed and monitored to enhance patients' functional recovery and quality of life. Pharmacotherapy also addresses issues like polypharmacy, inappropriate medication use, adverse drug reactions, and drug interactions, which can impact patients' daily living activities and overall health status.[6]

Pharmacotherapy is vital in optimizing medication regimens, ensuring proper dosing, monitoring for efficacy and side effects, and promoting adherence to treatment plans, especially in older adults and individuals with complex medical needs. The role of pharmacists in pharmacotherapy is crucial in providing comprehensive care, conducting medication reviews, educating patients and caregivers, and collaborating with healthcare professionals to enhance treatment outcomes and prevent medication-related problems. In conclusion, pharmacotherapy is indispensable in modern healthcare, offering a valuable tool for managing diseases, improving patient outcomes, and enhancing the overall quality of care provided to individuals across different age groups and health conditions.[7]

2. Scope of the Article

The scope of the review encompasses a comprehensive examination of pharmacotherapy strategies for managing metabolic and endocrine disorders. It covers a wide range of topics including diabetes mellitus, obesity, dyslipidemia, thyroid disorders, adrenal disorders, pituitary disorders, and gonadal disorders. The review discusses various pharmacological interventions, both oral and injectable, along with their mechanisms of action and clinical efficacy. Additionally, it addresses challenges such as medication adherence, side effects, individualized treatment approaches, and cost considerations. The review also explores emerging pharmacotherapy strategies and future directions in the field. Overall, it provides a thorough analysis of evidence-based pharmacotherapy options to optimize patient outcomes in the management of metabolic and endocrine disorders.

3. Metabolic disorders

Metabolic disorders are conditions that negatively impact the body's processing and distribution of macronutrients such as proteins, fats, and carbohydrates. They can be inborn errors of metabolism that occur when the metabolism process or certain organs fail to function properly. These disorders may result from genetic defects, hormone or enzyme deficiency, or abnormal chemical reactions that hinder metabolism. Some common types of

metabolic disorders include diabetes mellitus (type 1, type 2, and gestational), obesity, dyslipidemia, and metabolic syndrome are mentioned in Figure 1.[8–10]

3.1 Diabetes mellitus is a group of metabolic disorders characterized by high blood sugar levels due to the body's inability to produce or use insulin effectively. Type 1 diabetes is an autoimmune disorder where the body destroys the insulin-producing cells in the pancreas, requiring lifelong insulin injections. Type 2 diabetes is a metabolic disorder where the body becomes resistant to insulin or doesn't produce enough insulin, which can often be managed with lifestyle changes and medication. Gestational diabetes occurs during pregnancy and usually resolves after delivery, but it increases the risk of developing type 2 diabetes later in life.[11]

3.2 Obesity is a metabolic disorder characterized by excessive body fat accumulation, which can lead to various health problems, including heart disease, diabetes, and certain cancers.[12,13]

3.3 Dyslipidemia is a metabolic disorder that involves abnormal levels of cholesterol and other fats in the blood, which can increase the risk of heart disease and stroke.[14,15]

3.4 Metabolic Syndrome is a cluster of conditions, including obesity, high blood pressure, high blood sugar, and abnormal cholesterol levels, that increase the risk of heart disease, stroke, and diabetes.[16,17]

Figure 1: Metabolic disorders

4. Pharmacotherapy strategies for metabolic disorders, such as diabetes mellitus, obesity, and dyslipidemia, involve a variety of approaches, including systemic drug therapy, oral drug delivery, local drug delivery, targeted drug delivery, and intelligent stimulus-responsive drug delivery.

4.1 For diabetes mellitus, the subcutaneous injection of insulin is the most common approach for controlling hyperglycemia, while oral medications such as metformin, sulfonylureas, and dipeptidyl peptidase-4 (DPP-4) inhibitors are also used. Additionally, emerging novel delivery strategies, such as insulin pumps and continuous glucose monitors, are being studied to improve the management of diabetes.[18,19]

4.2 Obesity, weight management using diet, increased physical activity, and behavioral modification is essential. Pharmacotherapy strategies for obesity include the use of appetite suppressants, such as phentermine and orlistat, and drugs that affect energy metabolism, such as liraglutide and semaglutide.[20,21]

4.3 For dyslipidemia, statins are the most commonly used medication to lower cholesterol levels, while other medications, such as

ezetimibe and bile acid sequestrants, are also used.

Overall, pharmacotherapy strategies for metabolic disorders aim to improve the management of these conditions, reduce side effects, and improve patient compliance with treatment.[22,23]

5. Endocrine disorders

Endocrine disorders are medical conditions that result from dysfunction in the endocrine system, which is responsible for producing and regulating hormones throughout the body. The endocrine system consists of glands mentioned in Figure 2 such as the thyroid, adrenal, pituitary, and pancreas, among others, that secrete hormones directly into the bloodstream to control various physiological processes, including metabolism, growth and development, reproduction, mood regulation, and energy levels. [24]

5.1 Thyroid disorders are conditions that affect the thyroid gland, which is responsible for producing hormones that regulate metabolism. The two main types of thyroid disorders are hypothyroidism and hyperthyroidism.[25]

5.1.1 Hypothyroidism, also known as underactive thyroid, occurs when the thyroid gland does not produce enough thyroid hormones. This can lead to symptoms such as fatigue, weight gain, dry skin, and depression. Causes of hypothyroidism include Hashimoto's thyroiditis, surgical removal of part or all of the thyroid gland, radiation therapy for head and neck cancers, some medications, a damaged or missing thyroid gland, too much or too little iodine intake, Turner syndrome, pituitary gland damage, and an autoimmune condition. [26]

5.1.2 Hyperthyroidism, also known as overactive thyroid, occurs when the thyroid gland produces too much thyroid hormone. This can lead to symptoms such as rapid heartbeat, tremors, weight loss, and anxiety. Causes of hyperthyroidism include Graves' disease, multinodular goiter, toxic nodular goiter, thyroiditis, and taking too much thyroid hormone medication.[27]

5.2 Adrenal disorders encompass a range of conditions affecting the adrenal glands, which are responsible for producing essential hormones that regulate various bodily functions. Two significant adrenal disorders are Addison's disease and Cushing's syndrome.[28]

5.2.1 Addison's disease, also known as primary adrenal insufficiency, is a rare disorder characterized by the adrenal glands' inability to produce enough cortisol and aldosterone hormones. This condition can lead to symptoms such as fatigue, muscle weakness, weight loss, low blood pressure, darkened skin, and salt cravings. Addison's disease is usually caused by an autoimmune reaction where the body attacks the adrenal glands, disrupting hormone production. Treatment involves hormone replacement therapy to manage symptoms and ensure hormone balance.[29]

5.2.2 Cushing's syndrome, on the other hand, is a condition characterized by the overproduction of cortisol, often caused by prolonged exposure to high levels of the hormone. Symptoms of Cushing's syndrome include weight gain, particularly in the face, neck, and abdomen, thinning skin that bruises easily, muscle weakness, and fatigue. The condition can result from various factors, such as excessive use of corticosteroid medications, tumors in the pituitary or adrenal glands, or other underlying health issues.[30]

5.3 Pituitary disorders

5.3.1 Growth hormone deficiency is a rare disorder characterized by the inadequate secretion of growth hormone (GH) from the anterior pituitary gland, a small gland located at the base of the brain that is responsible for the production of several hormones GHD can be

present from birth (congenital), resulting from genetic mutations or from structural defects in the brain. It can also be acquired later in life as a result of trauma, infection, radiation therapy, or tumor growth within the brain. A third category has no known or diagnosable cause (idiopathic). Childhood-onset GHD may be all three: congenital, acquired, or idiopathic. It results in growth retardation, short stature, and maturation delays reflected by the delay of lengthening of the bones of the extremities that is inappropriate to the adult-onset GHD is most often is acquired from a pituitary tumor or trauma to the brain but may also be idiopathic. It is characterized by several variable symptoms including reduced energy levels, altered body composition, osteoporosis (reduced bone mineral density), reduced muscle strength, lipid abnormalities such as increased LDL cholesterol, insulin resistance, and impaired cardiac function.[31,32]

5.3.2 Acromegaly is a rare disorder characterized by excessive growth of certain parts of the body due to high levels of growth hormone (GH) after the growth plates have closed. The condition is typically caused by the pituitary gland producing excess growth hormone, with over 95% of cases attributed to a benign tumor called a pituitary adenoma. Symptoms of acromegaly include enlargement of the hands, feet, forehead, jaw, and nose, as well as joint pain, thicker skin, deepening of the voice, headaches, and vision problems. Complications may include type 2 diabetes, sleep apnea, high blood pressure, and heart issues. Diagnosis involves measuring growth hormone levels and insulin-like growth factor I in the blood, followed by medical imaging to detect the presence of a pituitary adenoma.[33]

5.4 Gonadal disorders are conditions that affect the gonads, which are the reproductive glands in both males and females. In males, the gonads are the testes, while in females, the gonads are the ovaries. Gonadal disorders can result from abnormal gonadal differentiation, defective endocrine function, or excessive endocrine activity.[34]

5.4.1 Hypogonadism is a deficiency in ovary or testicular function, leading to impotence, hair loss, infertility, and loss of libido in men, and poor ovary function, feminine or masculine sterility, and menopause in women. In women, hypogonadism can manifest in three forms: primary hypogonadism, central hypogonadism, and menopause. Primary hypogonadism is characterized by poor ovary function, while central hypogonadism results from an anomaly of the hypothalamo-hypophyseal axis, causing a decrease or a total stop of FSH and LH production. Menopause is also a particular form of hypogonadism. In men, hypogonadism is presented by a deficiency in testicular function, affecting sperm production and testosterone secretion. [35]

5.4.2 Polycystic ovary syndrome (PCOS) is a hormonal disorder common among women, causing irregular menstrual periods or excess male hormone levels. The ovaries may fail to regularly release eggs and may develop small follicles (collections of fluid). Symptoms of PCOS vary and may include irregular periods, excessive hair growth, acne, weight gain, and infertility.[36–38]



Figure 2: Endocrine Disorders

6. Pharmacotherapy Strategies for Endocrine Disorders

Pharmacotherapy strategies encompass a diverse array of treatments aimed at managing various medical conditions. Oral medications form a cornerstone in many treatment regimens, including those for diabetes management. Insulin sensitizers such as metformin and thiazolidinediones enhance insulin action, while secretagogues like sulfonylureas stimulate insulin release. Additionally, incretin-based therapies, such as GLP-1 agonists and DPP-4 inhibitors, offer novel mechanisms to regulate blood sugar levels effectively. Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent another class of oral medications for diabetes management, aiding in glucose excretion via the kidneys.[39]

Lipid-lowering agents, including statins, fibrates, and PCSK9 inhibitors, play a pivotal role in reducing cholesterol levels and mitigating cardiovascular risk. Injectable medications are frequently employed for conditions like diabetes, where insulin therapy is essential for glycemic control. GLP-1 agonists, administered via injection, offer an alternative for those requiring additional glucose-lowering therapy.[40]

In endocrine disorders, such as growth hormone deficiency or hypothyroidism, hormone replacement therapy becomes indispensable. Growth hormone replacement, using recombinant human growth hormone, addresses deficiencies in growth hormone production. Similarly, thyroid hormone replacement therapy, typically involving synthetic thyroid hormones like levothyroxine, restores thyroid hormone levels in individuals with hypothyroidism.[41]

Corticosteroids are widely used for their anti-inflammatory and immunosuppressive properties, making them crucial in managing conditions such as autoimmune diseases and adrenal insufficiency. Hormone replacement therapy for menopause, often involving estrogen alone or in combination with progestin, alleviates symptoms like hot flashes and vaginal dryness. Lastly, androgen replacement therapy is employed to restore testosterone levels in men with hypogonadism, contributing to improved quality of life and overall health. These pharmacotherapy strategies highlight the multifaceted approaches employed to address diverse medical conditions, aiming to optimize patient outcomes and well-being.[42]

7. Challenges and Considerations

The challenges and considerations related to medication adherence, side effects, individualized treatment approaches, cost considerations, and emerging therapies are crucial aspects in the management of chronic conditions and improving patient outcomes.

7.1 Adherence to Medication

Medication adherence is a critical factor in achieving therapeutic goals and improving patient outcomes. It involves the extent to which a person's behavior aligns with taking medication

optimally. Non-adherence can lead to reduced clinical benefits and significant waste of resources.[43]

7.2 Side Effects and Complications

Side effects and complications associated with medications can impact patient adherence. Patients may experience adverse effects that affect their willingness to continue treatment. Addressing side effects and complications is essential to ensure patient compliance and treatment efficacy.[44]

7.3 Individualized Treatment Approaches

Tailoring treatment approaches to individual patients' needs and preferences is key to promoting medication adherence. Personalized care accounts for factors such as lifestyle, cultural beliefs, and patient-specific challenges, enhancing treatment effectiveness and patient satisfaction.[45]

7.4 Cost Considerations

Cost can be a significant barrier to medication adherence, particularly for patients with chronic conditions. Access to affordable medications and financial support programs can help improve adherence rates and ensure patients can continue their treatment regimens.[46,47]

7.5 Emerging Therapies and Future Directions

Exploring emerging therapies and future directions in medication adherence can lead to innovative solutions to improve patient outcomes. Research into novel interventions, technology-driven adherence tools, and patient education initiatives can enhance adherence rates and overall healthcare quality[48,49]

8. Future Perspectives

Future pharmacotherapy strategies for metabolic and endocrine disorders are expected to advance significantly, driven by personalized medicine, novel therapeutic targets, and emerging biotechnologies. Precision medicine will tailor treatments based on individual patient characteristics, optimizing efficacy and minimizing side effects. Research into molecular mechanisms will uncover new drug targets, while biologics and gene editing offer innovative treatment approaches.[50,51] Combination therapies, advanced drug delivery systems, and digital health solutions will enhance treatment outcomes by targeting multiple pathways, improving adherence, and enabling real-time monitoring. In summary, future pharmacotherapy aims to revolutionize the management of metabolic and endocrine disorders through tailored, effective, and patient-centric approaches.[50]

9. Conclusion

Pharmacotherapy strategies for metabolic and endocrine disorders are undergoing rapid evolution, driven by advancements in personalized medicine, novel therapeutic targets, and innovative technologies. The future holds promise for tailored treatments that optimize efficacy while minimizing adverse effects through precision medicine approaches. Research into molecular mechanisms continues to uncover new drug targets, paving the way for the development of biologics, gene therapies, and combination therapies targeting multiple pathways. Advanced drug delivery systems and digital health solutions offer opportunities to enhance treatment outcomes by improving adherence and enabling real-time monitoring. Overall, future pharmacotherapy strategies aim to revolutionize the management of metabolic and endocrine disorders, providing patients with more effective, personalized, and patient-centric approaches to treatment.

References

1. Hotamisligil GS. Inflammation and metabolic disorders. *Nature*.

2006;444(7121):860-867. doi:10.1038/nature05485

2. Aron-Wisnewsky J, Warmbrunn M V., Nieuwdorp M, Clément K. Metabolism and Metabolic Disorders and the Microbiome: The Intestinal Microbiota Associated With Obesity, Lipid Metabolism, and Metabolic Health—Pathophysiology and Therapeutic Strategies. *Gastroenterology*. 2021;160(2):573-599. doi:10.1053/j.gastro.2020.10.057

3. Unuane D, Tournaye H, Velkeniers B, Poppe K. Endocrine disorders & female infertility. *Best Pract Res Clin Endocrinol Metab*. 2011;25(6):861-873. doi:10.1016/j.beem.2011.08.001

4. Michels AW, Eisenbarth GS. Immunologic endocrine disorders. *Journal of Allergy and Clinical Immunology*. 2010;125(2 SUPPL. 2). doi:10.1016/j.jaci.2009.09.053

5. Pal R, Bhadada SK. Managing common endocrine disorders amid COVID-19 pandemic. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(5):767-771. doi:10.1016/j.dsx.2020.05.050

6. Itoh N, Ohta H, Konishi M. Endocrine FGFs: Evolution, physiology, pathophysiology, and pharmacotherapy. *Front Endocrinol (Lausanne)*. 2015;6. doi:10.3389/fendo.2015.00154

7. Horska K, Ruda-Kucerova J, Kotolová H. *Metabolic Syndrome-Dysregulation of Adipose Tissue Endocrine Function*.; 2014. https://www.researchgate.net/publication/266029223

8. Gyamfi J, Kim J, Choi J. Cancer as a Metabolic Disorder. *Int J Mol Sci*. 2022;23(3). doi:10.3390/ijms23031155

9. Heindel JJ, Blumberg B, Cave M, et al. Metabolism disrupting chemicals and metabolic disorders. *Reproductive Toxicology*. 2017;68:3-33. doi:10.1016/j.reprotox.2016.10.001

10. Tabatabaei-Malazy O, Larijani B, Abdollahi M. Targeting metabolic disorders by natural products. *J Diabetes Metab Disord*. 2015;14(1). doi:10.1186/s40200-015-0184-8

11. Pradhan A. Obesity, Metabolic Syndrome, and Type 2 Diabetes: Inflammatory Basis of Glucose Metabolic Disorders. *Nutr Rev*. 2008;65(12):152-156. doi:10.1301/nr.2007.dec.s152-s156

12. Rani V, Deep G, Singh RK, Palle K, Yadav UCS. Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. *Life Sci*. 2016;148:183-193. doi:10.1016/j.lfs.2016.02.002

13. Ferreira CR, Rahman S, Keller M, et al. An international classification of inherited metabolic disorders (ICIMD). *J Inherit Metab Dis*. 2021;44(1):164-177. doi:10.1002/jimd.12348

14. Rottiers V, Näär AM. MicroRNAs in metabolism and metabolic disorders. *Nat Rev Mol Cell Biol*. 2012;13(4):239-251. doi:10.1038/nrm3313

15. Kahler SG, Fahey MC. Metabolic disorders and mental retardation. *American Journal of Medical Genetics - Seminars in Medical Genetics*. 2003;117 C(1):31-41. doi:10.1002/ajmg.c.10018

16. Navab M, Gharavi N, Watson AD. *Inflammation and Metabolic Disorders*. http://www.nhlbi.nih.gov/about/fra-

17. *Metabolic Disorders Related to Obesity and Periodontal Disease*.

18. Sanz Y, Santacruz A, Gauffin P. Gut microbiota in obesity and metabolic disorders. In: *Proceedings of the Nutrition Society*. Vol 69. ; 2010:434-441. doi:10.1017/S0029665110001813

19. Ghemrawi R, Battaglia-Hsu SF, Arnold C. Endoplasmic reticulum stress in metabolic

disorders. *Cells*. 2018;7(6). doi:10.3390/cells7060063

20. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: The Bruneck Study. *Diabetes*. 1998;47(10):1643-1649. doi:10.2337/diabetes.47.10.1643

21. Shin DW. Lipophagy: Molecular Mechanisms and Implications in Metabolic Disorders. *Mol Cells*. 2020;43(8):686-693. doi:10.14348/molcells.2020.0046

22. Goff JP, Horst RL. Physiological Changes at Parturition and Their Relationship to Metabolic Disorders. *J Dairy Sci*. 1997;80(7):1260-1268. doi:10.3168/jds.S0022-0302(97)76055-7

23. Gong J, Sun Z, Li P. CIDE proteins and metabolic disorders. *Curr Opin Lipidol*. 2009;20(2):121-126. doi:10.1097/MOL.0b013e328328d0bb

24. Maqbool F, Mostafalou S, Bahadar H, Abdollahi M. Review of endocrine disorders associated with environmental toxicants and possible involved mechanisms. *Life Sci*. 2016;145:265-273. doi:10.1016/j.lfs.2015.10.022

25. Devendra D, Eisenbarth GS. 17. Immunologic endocrine disorders. *Journal of Allergy and Clinical Immunology*. 2003;111(2 SUPPL. 2). doi:10.1067/mai.2003.81

26. Yu J. Endocrine disorders and the neurologic manifestations. *Ann Pediatr Endocrinol Metab*. 2014;19(4):184. doi:10.6065/apem.2014.19.4.184

27. Kapoor D, Jones TH. Smoking and hormones in health and endocrine disorders. *Eur J Endocrinol*. 2005;152(4):491-499. doi:10.1530/eje.1.01867

28. Lause M, Kamboj A, Faith EF. Dermatologic manifestations of endocrine disorders. *Transl Pediatr*. 2017;6(4):300-312. doi:10.21037/tp.2017.09.08

29. Musselman DL, Nemeroff CB. *Depression and Endocrine Disorders: Focus on the Thyroid and Adrenal System*.; 1996.

30. Darbre PD. Overview of air pollution and endocrine disorders. *Int J Gen Med*. 2018;11:191-207. doi:10.2147/IJGM.S102230

31. Newman CB, Blaha MJ, Boord JB, et al. Lipid management in patients with endocrine disorders: An endocrine society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism*. 2020;105(12). doi:10.1210/clinem/dgaa674

32. Geffken GR, Ward HE, Staab JP, Carmichael SLK, Evans DL. *PSYCHIATRIC MORBIDITY IN ENDOCRINE DISORDERS*.

33. Eller-Vainicher C, Falchetti A, Gennari L, et al. Diagnosis of Endocrine Disease: Evaluation of bone fragility in endocrine disorders. *Eur J Endocrinol*. 2019;180(6):R213-R232. doi:10.1530/EJE-18-0991

34. Connery LE, Coursin DB. Assessment and therapy of selected endocrine disorders. *Anesthesiol Clin North Am*. 2004;22(1):93-123. doi:10.1016/S0889-8537(03)00111-1

35. Bhasin S, Enzlin P, Coviello A, Basson R. *Sexual Dysfunction 3 Sexual Dysfunction in Men and Women with Endocrine Disorders*. Vol 369.; 2007. www.thelancet.com

36. Golbidi S, Laher I. *Antioxidant Therapy in Human Endocrine Disorders*.; 2010. http://www.medscimonit.com/fulltxt.php?ICID=878307

37. Ulhôa MA, Marqueze EC, Burgos LGA, Moreno CRC. Shift work and endocrine disorders. *Int J Endocrinol*. 2015;2015. doi:10.1155/2015/826249

38. Schaefer AM, Walker M, Turnbull DM, Taylor RW. Endocrine disorders in

mitochondrial disease. *Mol Cell Endocrinol*. 2013;379(1-2):2-11. doi:10.1016/j.mce.2013.06.004

39. van Hulsteijn LT, Pasquali R, Casanueva F, et al. Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis. *Eur J Endocrinol*. 2020;182(1):11-21. doi:10.1530/EJE-19-0666

40. Feldt-Rasmussen U, Mathiesen ER. Endocrine disorders in pregnancy: Physiological and hormonal aspects of pregnancy. *Best Pract Res Clin Endocrinol Metab*. 2011;25(6):875-884. doi:10.1016/j.beem.2011.07.004

41. Kucharska AM, Witkowska-Sędek E, Rumińska M, Pyrżak B. Thyroid hormone changes related to growth hormone therapy in growth hormone deficient patients. *J Clin Med*. 2021;10(22). doi:10.3390/jcm10225354

42. Salazar D, Rey V, Neves JS, et al. Treatment of Isolated Idiopathic Growth Hormone Deficiency in Children and Thyroid Function: Is the Need for LT4 Supplementation a Concern in Long-Term Therapy? *Cureus*. Published online January 30, 2022. doi:10.7759/cureus.21722

43. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. *Endocr Rev*. 2014;35(6):992-1019. doi:10.1210/er.2014-1035

44. Mariadoss AVA, Sivakumar AS, Lee CH, Kim SJ. Diabetes mellitus and diabetic foot ulcer: Etiology, biochemical and molecular based treatment strategies via gene and nanotherapy. *Biomedicine and Pharmacotherapy*. 2022;151. doi:10.1016/j.biopha.2022.113134

45. Gao Y, Xu T, Zhao YX, et al. A Novel Network Pharmacology Strategy to Decode Metabolic Biomarkers and Targets Interactions for Depression. *Front Psychiatry*. 2020;11. doi:10.3389/fpsyt.2020.00667

46. Neeland IJ, Poirier P, Després JP. Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management. *Circulation*. 2018;137(13):1391-1406. doi:10.1161/CIRCULATIONAHA.117.029617

47. Kumari Y, Bai P, Waqar F, et al. Advancements in the Management of Endocrine System Disorders and Arrhythmias: A Comprehensive Narrative Review. *Cureus*. Published online October 4, 2023. doi:10.7759/cureus.46484

48. Barres R, Zierath JR. DNA methylation in metabolic disorders. In: *American Journal of Clinical Nutrition*. Vol 93. ; 2011. doi:10.3945/ajcn.110.001933

49. Cruz Rivera S, Kyte DG, Aiyegbusi OL, Keeley TJ, Calvert MJ. Assessing the impact of healthcare research: A systematic review of methodological frameworks. *PLoS Med*. 2017;14(8). doi:10.1371/journal.pmed.1002370

50. Islam MR, Rauf A, Akash S, et al. Targeted therapies of curcumin focus on its therapeutic benefits in cancers and human health: Molecular signaling pathway-based approaches and future perspectives. *Biomedicine and Pharmacotherapy*. 2024;170. doi:10.1016/j.biopha.2023.116034

51. Wang Y, Chen S, Wang C, Guo F. Nanocarrier-based targeting of metabolic pathways for endometrial cancer: Status and future perspectives. *Biomedicine and Pharmacotherapy*. 2023;166. doi:10.1016/j.biopha.2023.115348